Samantha Bobba1, Connor Devlin2, Nick Di Girolamo3, Denis Wakefield4,3, Peter McCluskey2,5, Elsie Chan6, Mark Daniell6, Stephanie Watson7,8,9. 1. Prince of Wales Clinical School, University of New South Wales, High Street, Randwick, Sydney, NSW, 2031, Australia. Samantha.bobba@gmail.com. 2. Sydney Eye Hospital, Sydney, Australia, 8 Macquarie Street, Sydney, NSW, 2000, Australia. 3. School of Medical Sciences, University of New South Wales, Kensington, Sydney, NSW, 2052, Australia. 4. Prince of Wales Clinical School, University of New South Wales, High Street, Randwick, Sydney, NSW, 2031, Australia. 5. Save Sight Institute, University of Sydney, 8 Macquarie Street, Sydney, NSW, 2000, Australia. 6. Royal Victorian Eye and Ear Hospital, Centre for Eye Research Australia, University of Melbourne, 32 Gisbourne Street, East Melbourne, VIC, 3002, Australia. 7. Prince of Wales Clinical School, University of New South Wales, High Street, Randwick, Sydney, NSW, 2031, Australia. Stephanie.watson@sydney.edu.au. 8. Sydney Eye Hospital, Sydney, Australia, 8 Macquarie Street, Sydney, NSW, 2000, Australia. Stephanie.watson@sydney.edu.au. 9. Save Sight Institute, University of Sydney, 8 Macquarie Street, Sydney, NSW, 2000, Australia. Stephanie.watson@sydney.edu.au.
Abstract
AIMS: This study aimed to determine the incidence, clinical features and management of cicatrising conjunctivitis in Australia and New Zealand, also enabling comparison with data from the United Kingdom. METHODS: A prospective surveillance study was conducted over 17 months via the Australian and New Zealand Ophthalmic Surveillance Unit with a one-year follow-up period. Practicing ophthalmologists on the Surveillance Unit's database were asked to report recently diagnosed cases of cicatrising conjunctivitis on a monthly basis. Initial and follow-up questionnaires were sent to ophthalmologists who had reported positive cases to obtain demographic and clinical data. The minimum incidence of cicatrising conjunctivitis was calculated based on cases reported during the study period and from population data. RESULTS: During the 17-month study period (December 2011-April 2013), 56 cases of cicatrising conjunctivitis were reported. Data was obtained for 35 cases (62%) with a mean age of 74 years (range, 28-94 years). The most common aetiologies were ocular mucus membrane pemphigoid (n = 18 cases, 51.4%), Stevens-Johnson Syndrome (n = 3, 8.6%) and graft versus host disease (n = 3, 8.6%). The minimum incidence of cicatrising conjunctivitis in Australia and New Zealand was 1.5 per million, comparable to incidence data from the United Kingdom. CONCLUSIONS: This study is the first to prospectively record the incidence of cicatrising conjunctivitis in Australia and New Zealand and the second worldwide. It provides novel data on demographics and management of cicatrising conjunctivitis, as reported by treating ophthalmologists.
AIMS: This study aimed to determine the incidence, clinical features and management of cicatrising conjunctivitis in Australia and New Zealand, also enabling comparison with data from the United Kingdom. METHODS: A prospective surveillance study was conducted over 17 months via the Australian and New Zealand Ophthalmic Surveillance Unit with a one-year follow-up period. Practicing ophthalmologists on the Surveillance Unit's database were asked to report recently diagnosed cases of cicatrising conjunctivitis on a monthly basis. Initial and follow-up questionnaires were sent to ophthalmologists who had reported positive cases to obtain demographic and clinical data. The minimum incidence of cicatrising conjunctivitis was calculated based on cases reported during the study period and from population data. RESULTS: During the 17-month study period (December 2011-April 2013), 56 cases of cicatrising conjunctivitis were reported. Data was obtained for 35 cases (62%) with a mean age of 74 years (range, 28-94 years). The most common aetiologies were ocular mucus membrane pemphigoid (n = 18 cases, 51.4%), Stevens-Johnson Syndrome (n = 3, 8.6%) and graft versus host disease (n = 3, 8.6%). The minimum incidence of cicatrising conjunctivitis in Australia and New Zealand was 1.5 per million, comparable to incidence data from the United Kingdom. CONCLUSIONS: This study is the first to prospectively record the incidence of cicatrising conjunctivitis in Australia and New Zealand and the second worldwide. It provides novel data on demographics and management of cicatrising conjunctivitis, as reported by treating ophthalmologists.
Authors: Lawrence S Chan; A Razzaque Ahmed; Grant J Anhalt; Wolfgang Bernauer; Kevin D Cooper; Mark J Elder; Jo-David Fine; C Stephen Foster; Reza Ghohestani; Takashi Hashimoto; Thanh Hoang-Xuan; Gudula Kirtschig; Neil J Korman; Susan Lightman; Francina Lozada-Nur; M Peter Marinkovich; Bartly J Mondino; Catherine Prost-Squarcioni; Roy S Rogers; Jane F Setterfield; Dennis P West; Fenella Wojnarowska; David T Woodley; Kim B Yancey; Detlef Zillikens; John J Zone Journal: Arch Dermatol Date: 2002-03
Authors: Samantha Bobba; Nick Di Girolamo; Richard Mills; Mark Daniell; Elsie Chan; Damien G Harkin; Brendan G Cronin; Geoffrey Crawford; Charles McGhee; Stephanie Watson Journal: Clin Exp Ophthalmol Date: 2016-09-01 Impact factor: 4.207
Authors: P Bernard; L Vaillant; B Labeille; C Bedane; B Arbeille; J P Denoeux; G Lorette; J M Bonnetblanc; C Prost Journal: Arch Dermatol Date: 1995-01
Authors: Borja de la Sen-Corcuera; Jesús Montero-Iruzubieta; Ronald M Sánchez-Ávila; Gorka Orive; Eduardo Anitua; Manuel Caro-Magdaleno; Jesús Merayo-Lloves Journal: Clin Ophthalmol Date: 2020-06-17
Authors: H Rashid; A Lamberts; L Borradori; S Alberti-Violetti; R J Barry; M Caproni; B Carey; M Carrozzo; F Caux; G Cianchini; A Corrà; G F H Diercks; F G Dikkers; G Di Zenzo; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; A V Marzano; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; C Prost; S Rauz; B D van Rhijn; M Roth; E Schmidt; J Setterfield; G Zambruno; D Zillikens; B Horváth Journal: J Eur Acad Dermatol Venereol Date: 2021-07-10 Impact factor: 6.166